Amy E. Juedes

Array ( [id] => 17292551 [patent_doc_number] => 20210388390 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => INTRACELLULAR DELIVERY OF BIOMOLECULES TO ENHANCE ANTIGEN PRESENTING CELL FUNCTION [patent_app_type] => utility [patent_app_number] => 17/282709 [patent_app_country] => US [patent_app_date] => 2019-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -110 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17068592 [patent_doc_number] => 20210270807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => MOT CELLS AS A THERAPEUTIC SCREENING TOOL FOR REGULATORY T-CELL ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/256592 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243502 [patent_doc_number] => 20210363245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/276959 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17742621 [patent_doc_number] => 11390678 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-19 [patent_title] => Compositions and methods for the treatment of immune related diseases [patent_app_type] => utility [patent_app_number] => 16/537280 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 87 [patent_no_of_words] => 51101 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16537280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145117 [patent_doc_number] => 20190351036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/530104 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19977200 [patent_doc_number] => 12344661 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination [patent_app_type] => utility [patent_app_number] => 16/502498 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 14527 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19977200 [patent_doc_number] => 12344661 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination [patent_app_type] => utility [patent_app_number] => 16/502498 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 14527 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432395 [patent_doc_number] => 20200030380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLS [patent_app_type] => utility [patent_app_number] => 16/502433 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227987 [patent_doc_number] => 12416636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Personalized treatment of pancreatic cancer [patent_app_type] => utility [patent_app_number] => 17/059727 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 32 [patent_no_of_words] => 9143 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17059727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227987 [patent_doc_number] => 12416636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Personalized treatment of pancreatic cancer [patent_app_type] => utility [patent_app_number] => 17/059727 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 32 [patent_no_of_words] => 9143 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17059727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145083 [patent_doc_number] => 20190351019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => STEROID ADMINISTRATION AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/421763 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16794102 [patent_doc_number] => 20210123919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/052133 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16794102 [patent_doc_number] => 20210123919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/052133 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15180883 [patent_doc_number] => 20190361033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/407699 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432385 [patent_doc_number] => 20200030375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS [patent_app_type] => utility [patent_app_number] => 16/404091 [patent_app_country] => US [patent_app_date] => 2019-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16404091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836271 [patent_doc_number] => 20190276536 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => HUMANIZED ANTIBODIES WITH INCREASED STABILITY [patent_app_type] => utility [patent_app_number] => 16/398472 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20838 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14806395 [patent_doc_number] => 20190269807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => SOLUBLE TCR MOLECULES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/398226 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956047 [patent_doc_number] => 11059889 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Anti-human Igb antibody [patent_app_type] => utility [patent_app_number] => 16/392418 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 15218 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 313 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147831 [patent_doc_number] => 20190352393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS [patent_app_type] => utility [patent_app_number] => 16/389356 [patent_app_country] => US [patent_app_date] => 2019-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16389356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715681 [patent_doc_number] => 20190248904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => NOVEL ANTI-HUMAN BDCA-2 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/384811 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384811 [rel_patent_id] =>[rel_patent_doc_number] =>)